Compare RH & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RH | MLYS |
|---|---|---|
| Founded | 1979 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2011 | 2023 |
| Metric | RH | MLYS |
|---|---|---|
| Price | $129.35 | $15.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 11 |
| Target Price | ★ $163.76 | $43.56 |
| AVG Volume (30 Days) | 711.4K | ★ 1.9M |
| Earning Date | 12-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.31 | 37.43 |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $1,193,046,000.00 | N/A |
| Revenue This Year | $5.68 | N/A |
| Revenue Next Year | $9.26 | N/A |
| P/E Ratio | $54.88 | ★ N/A |
| Revenue Growth | ★ 24.52 | N/A |
| 52 Week Low | $106.30 | $14.78 |
| 52 Week High | $239.40 | $45.00 |
| Indicator | RH | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 46.44 | 32.09 |
| Support Level | $123.55 | N/A |
| Resistance Level | $137.90 | $31.19 |
| Average True Range (ATR) | 7.60 | 1.53 |
| MACD | -1.24 | -0.05 |
| Stochastic Oscillator | 14.50 | 7.66 |
RH is a luxury furniture and lifestyle retailer primarily operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories, including furniture, lighting, textiles, bath, decor, and has a growing presence in hospitality with 27 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across design subcategories (RH Estates and Waterworks, for example), and has recently broadened its addressable market via expansion abroad (currently, less than 10% of sales) and its World of RH digital platform (highlighting offerings outside of home furnishings).
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.